Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 01; 366(9):799-807.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.